DE2050072B2 - - Google Patents

Info

Publication number
DE2050072B2
DE2050072B2 DE19702050072 DE2050072A DE2050072B2 DE 2050072 B2 DE2050072 B2 DE 2050072B2 DE 19702050072 DE19702050072 DE 19702050072 DE 2050072 A DE2050072 A DE 2050072A DE 2050072 B2 DE2050072 B2 DE 2050072B2
Authority
DE
Germany
Prior art keywords
aluminum
acetyl
glycyrrhetinate
tri
glycyrrhetinic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19702050072
Other languages
German (de)
Other versions
DE2050072A1 (en
DE2050072C3 (en
Inventor
Attilio Mailand Bonati (Italien)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INVERNI DELLA BEFFA SpA MAILAND (ITALIEN)
Original Assignee
INVERNI DELLA BEFFA SpA MAILAND (ITALIEN)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INVERNI DELLA BEFFA SpA MAILAND (ITALIEN) filed Critical INVERNI DELLA BEFFA SpA MAILAND (ITALIEN)
Priority to DE19702050072 priority Critical patent/DE2050072C3/en
Publication of DE2050072A1 publication Critical patent/DE2050072A1/en
Publication of DE2050072B2 publication Critical patent/DE2050072B2/de
Application granted granted Critical
Publication of DE2050072C3 publication Critical patent/DE2050072C3/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

3 43 4

Aluminiumhydroxid 16 g SalbeAluminum hydroxide 16 g of ointment

Verdünnungsmittel, wie Nairium-Diluents, such as nairium

alginat, Talk, Magnesiumstearat, Aluminium-tri-S-acetyl-ie/S-gly-alginate, talc, magnesium stearate, aluminum-tri-S-acetyl-ie / S-gly-

Polyoxyäthylenstearat, Stärke cyrrhetinat 2 gPolyoxyethylene stearate, starch cyrrhetinate 2 g

und/oder Lactose bis zu 100 g 5 Lidocain-P-Diäthylamino^'.o'-acet-and / or lactose up to 100 g 5 lidocaine-P-diethylamino ^ '. o'-acet-

oxylidid)-hydrochlorid 2 goxylidide) hydrochloride 2 g

Suppositorien Destilliertes Wasser 14,8 gSuppositories Distilled water 14.8 g

Methyl-p-hydroxybenzoat 0,2 gMethyl p-hydroxybenzoate 0.2 g

Aluminium-tri-3-acetyl-18/3-gly- Verdünnungsmittel, wie Polyäthy-Aluminum tri-3-acetyl-18/3-gly diluents, such as polyethylene

cyrrhetinat 100 mg io lenglykol 4000, Propylenglykolcyrrhetinate 100 mg io lenglykol 4000, propylene glycol

Tri-glyceride von Fettsäuren bis zu 1400 g und/oder Cerylalkohol bis zu .. 100 gTri-glycerides of fatty acids up to 1400 g and / or ceryl alcohol up to .. 100 g

Claims (3)

1 2 Aus der deutschen Auslegeschrift 1176 684 ist Patentansprüche: femer ein Verfahren zur Herstellung von Verbindungen der Glycyrrhetinsäure, wie dem Dinatriumsalz von1 2 From the German Auslegeschrift 1176 684 is patent claims: furthermore a process for the preparation of compounds of glycyrrhetinic acid, such as the disodium salt of 1. Alurainium-trW-acetyl-lS/J-glycyiThetinat. Glycyrrhetinsäure-Hemisuccinat und dem Dinatrium-1. Alurainium-trW-acetyl-IS / J-glycyiThetinate. Glycyrrhetinic acid hemisuccinate and disodium 2. Verfahren zur HersteJlung der Verbindung 5 salz des Glycyrrhetinsäure-Dihydrogenphosphates begemäß Anspruch 1, daaurch gekenn- kannt.2. Process for the preparation of the compound 5 salt of glycyrrhetinic acid dihydrogen phosphate accordingly Claim 1, known thereby. zeichnet, daß man S-Acetyl-ie^-glycyrrhetin- Von den Verbindungen der Auslegeschrift war auchdraws that one S-Acetyl-ie ^ -glycyrrhetin- was also from the compounds of the Auslegeschrift säure mit einem in an sich bekannter Weise bekannt, daß sie bei der Bekämpfung entzündlicheracid with a known in a manner that they fight inflammatory niederen Alkanolat mit 1 bis 4 C-Atomen bei Erscheinungen mancher Art, unter anderem von ulcera-lower alkanolate with 1 to 4 carbon atoms with symptoms of some kinds, including ulcer Raumtemperatur oder erhöhter lemperatur, zweck- io tiven Erscheinungen des Verdauungskanals, wertvollRoom temperature or elevated temperature, purposeful phenomena of the digestive tract, are valuable mäßig in Gegenwart eines organischen Lösungs- sind,are moderately in the presence of an organic solution, mittels, umsetzt. Bei Untersuchungen über die Antiulcus-Wirksam-by means of, implements. When investigating the antiulcus efficacy 3. Pharmazeutische Zubereitungen, gekenn- keit von Aluminium-tri-3-acetyl-glycyrrhetinat, Aluzeichnet durch einen Gehalt an der Verbindung miniumglycyrrhetinat, Glycyrrhetinsäure, 3-o-Acetylnach Anspruch 1 zusammen mit einem pharma- 15 Glycyrrhetinsäure und von Natrium-Hemisuccinylzeutisch annehmbaren Verdünnungsmittel oder glycyrrhetinsäure hat sich nun ergeben, daß das Träger. Aluminium-tri-3-acetyl-glycyrrhetinat die höchste An-3. Pharmaceutical preparations, labeled with aluminum tri-3-acetyl-glycyrrhetinate by a content of the compound miniumglycyrrhetinat, Glycyrrhetinsäure, 3-o-Acetylnach Claim 1 together with a pharmaceutical 15 glycyrrhetinic acid and sodium hemisuccinylzeutisch acceptable diluent or glycyrrhetinic acid has now been found that the Carrier. Aluminum tri-3-acetyl-glycyrrhetinate the highest tiulcus-Wirksamkeit aufweist Nur die Antiulcus-Wirksamkeit von Aluminiumglycyrrhetinat reicht anHas tiulcus effectiveness Only antiulcus effectiveness of aluminum glycyrrhetinate is sufficient ao diese Wirksamkeit heran. Das Aluminiumglycyrrhetinat weist dafür aber eine relativ geringe antünflammatorische Wirksamkeit auf.ao this effectiveness approach. The aluminum glycyrrhetinate but has a relatively low anti-inflammatory effect Effectiveness on. Die vorliegende Erfindung betrifft Aluminium- Bei Untersuchungen über die antiiaflammatorischeThe present invention relates to aluminum in studies of anti-inflammatory properties tri-S-acetyl-ie/S-glycyrrhetinat, Verfahren zu seiner Wirksamkeit von Aluminium-tri-3-acetyl-glycyrrhe-Herstellung und dieses enthaltende pharmazeutische 25 tinat, Aluminiumglycyrrhetinat und Glycyrrhetinsäure Zubereitungen. wurde das Aluminium-tri-3-acetyl-glycyrrhetinat alstri-S-acetyl-ie / S-glycyrrhetinate, process for its effectiveness by aluminum tri-3-acetyl-glycyrrhe manufacture and pharmaceutical tinate containing it, aluminum glycyrrhetinate and glycyrrhetinic acid Preparations. the aluminum tri-3-acetyl-glycyrrhetinate as Es wurde überraschenderweise gefunden, daß das wirksamste Substanz befunden.
Aluminium-tri-3-acetyl-18/?-glycyrrhetinat optimal Bei Toxizitätsuntersuchungen hat sich herausge-
It was surprisingly found that the most effective substance was found.
Aluminum tri-3-acetyl-18 /? - glycyrrhetinate optimal
heilwirksame und anti-inflammatorische Eigenschaften stellt, daß das Aluminium-tri-3-acetyl-glycyrrhetinat besitzt, das bei der Behandlung von Störungen des 30 weniger toxisch ist als Glycyrrhetinsäure und Na-Verdauungskanals, wie Magen- und Zwölffingerdarm- triumhemisuccinyl-glycyrrhetinat, insbesondere bei Geschwüre, Gastritis und Gastroduodenitis, insbeson- intraperitonealer Verabreichung,
dere jedoch bei durch Medikamente bewirkten Die folgenden Beispiele erläutern die Erfindung.
Medicinal and anti-inflammatory properties are provided by aluminum tri-3-acetyl-glycyrrhetinate, which is less toxic in the treatment of disorders of the 30 than glycyrrhetinic acid and Na digestive tract, such as gastric and duodenal triumhemisuccinyl-glycyrrhetinate, in particular for ulcers, gastritis and gastroduodenitis, especially intraperitoneal administration,
however, when medicated. The following examples illustrate the invention.
Störungen, sehr brauchbar ist. Diese Substanz kann . · 1 1Interference, is very useful. This substance can. · 1 1 darüber hinaus in der Therapie der Pharyngitis, 35 B e 1 s ρ 1 e 1 1in addition, in the therapy of pharyngitis, 35 B e 1 s ρ 1 e 1 1 Pharyngotracheitis, Hornhautgeschwüre, Kolitis (ins- 15,38 g S-Acetyl-lS/J-glycyrrhetinsäure, gelöst inPharyngotracheitis, corneal ulcers, colitis (ins- 15.38 g S-acetyl-IS / J-glycyrrhetinic acid, dissolved in besondere ulceröse Kolitis), Dermatitis, Dormatosis, 500 ml Chloroform, wurden zu einer Lösung von Dekubitalgeschwüre, latenten Ulcera, Krampfader- 2,04 g Aluminiumisopropylat in 50 ml Chloroform Geschwüre, Fissuren, Hämorrhoiden und Epithe'ero- zugegeben.special ulcerative colitis), dermatitis, dormatosis, 500 ml of chloroform, became a solution of Decubitus ulcers, latent ulcers, varicose veins - 2.04 g of aluminum isopropylate in 50 ml of chloroform Ulcers, fissures, hemorrhoids and epithe'ero- added. sionen der weiblichen Genitalpassagen angewandt 40 Nach 1 Stunde wurde die Chloroform-Lösung zur werden. Trockene abgedampft und Aluminium-tri-3-acetyl-Sions of the female genital passages applied 40 After 1 hour, the chloroform solution became will. Dry evaporated and aluminum-tri-3-acetyl- Die pharmazeutischen Zubereitungen können zu- 18/3-glycyrrhetinat als weißes Pulver erhalten, Schmelzsätzlich andere Arzneimittel enthalten. Brauchbare punkt 286 bis 29O0C. (<*]? = 126° ±2° (c = 1, Träger sind Stärke, Talk, Natriumalginat und CHCl3).The pharmaceutical preparations can also contain 18/3 glycyrrhetinate as a white powder, enamel generally contain other drugs. Usable point 286 to 29O 0 C. (<*]? = 126 ° ± 2 ° (c = 1, carriers are starch, talc, sodium alginate and CHCl 3 ). Magnesiumstearat. Die Zubereitungen können in 45 B e i s 0 i e 1 2Magnesium stearate. The preparations can be used in 45 B e i s 0 i e 1 2 Form von Tabletten oder Suppositorien oder alsForm of tablets or suppositories or as Pulver oder Salben verabreicht werden. Die pharma- 4,08 g Aluminiumisopropylat, gelöst in 50 ml Me-Powders or ointments are administered. The pharmaceutical 4.08 g of aluminum isopropylate, dissolved in 50 ml of zeutischen Zubereitungen können ebenso Mittel thylenchlorid, wurden zu 30,76 g 3-Acetyl-18/?-glygegen Hyperacidität, wie Aluminiumhydroxid, Glycin cyrrhetinsäure, gelöst in 200 ml Methylenchlorid, und Aluminiumsilicat, enthalten. go gegeben. Zur Vervollständigung der Lösung wurdeZeutischen preparations can also means ethylene chloride, were to 30.76 g of 3-acetyl-18 /? - gly against Hyperacidity, such as aluminum hydroxide, glycine cyrrhetinic acid, dissolved in 200 ml methylene chloride, and aluminum silicate. go given. To complete the solution was Das Verfahren zur Herstellung von Aluminium- bei Raumtemperatur gerührt, dann auf etwa 50 ml tri-3-acetyl-18/?-glycyrrhetinat ist dadurch gekenn- eingeengt und in 200 ml Hexan gegossen. Aluminiumzeichnet, daß man 3-Acetyl-18/?-glycyrrhetinsäure in tri-3-acetyl-18/3-glycyrrhetinat wurde als weißes, amoran sich bekannter Weise mit einem niederen Alkanolat phes, leichtes Pulver durch Filtration erhalten,
mit 1 bis 4 C-Atomen bei Zimmertemperatur oder 55 Mit der erfindungsgemäßen Verbindung können erhöhter Temperatur, zweckmäßig in Gegenwart eines folgende Rezepturen erhalten werden:
organischen Lösungsmittels, umsetzt. Als organische „ ,
The process for the production of aluminum - stirred at room temperature, then on about 50 ml of tri-3-acetyl-18 /? - glycyrrhetinate is thereby marked- concentrated and poured into 200 ml of hexane. Aluminum draws that 3-acetyl-18 /? -Glycyrrhetinic acid in tri-3-acetyl-18/3-glycyrrhetinate was obtained as a white, amoraneously known manner with a lower alkanolate phes, light powder by filtration,
with 1 to 4 carbon atoms at room temperature or 55 With the compound according to the invention at elevated temperature, advantageously in the presence of one of the following formulations, can be obtained:
organic solvent. As organic ",
Lösungsmittel können Alkohole, Äther, Ketone, I aWettenSolvents can be alcohols, ethers, ketones, bets chlorierte Lösungsmittel (Methylenchlorid, Chloro- Aluminium-tri-3-acetyl-18/S-gly-chlorinated solvents (methylene chloride, chloro-aluminum-tri-3-acetyl-18 / S-gly- form), Äthylacetat usw. verwendet werden. 60 cyrrhetinat 50 mgform), ethyl acetate, etc. can be used. 60 cyrrhetinate 50 mg In vielen Fällen ist die Löslichkeit des Salzes in Aluminiumhydroxid 400 mgIn many cases the solubility of the salt in aluminum hydroxide is 400 mg organischen Lösungsmitteln groß, während die Löslich- Verdünnungsmittel, wie Natrium-organic solvents, while the soluble diluents such as sodium keit in Wasser im allgemeinen niedrig ist. alginat, Magnesiumstearat, Talkspeed in water is generally low. alginate, magnesium stearate, talc Aus der deutschen Auslegeschrift 1184 753 ist ein und/oder Stärke bis zu 1,2 gFrom the German Auslegeschrift 1184 753 is a and / or strength up to 1.2 g Verfahren zur Herstellung von 3-Ketoglycyrrhetin- 65Process for the preparation of 3-ketoglycyrrhetine-65 säuren bekannt. Es geht aus dieser Auslegeschrift auch ruderacids known. There is also ruder from this explanatory document hervor, daß sich die Glycyrrhetinsäuren für die Aluminium - tri - 3 - acetyl -18/3 - gly-show that the glycyrrhetinic acids for the aluminum - tri - 3 - acetyl -18/3 - gly- Behandlung von Entzündungserscheinungen eignen. cyrrhetinat 3 gTreatment of symptoms of inflammation are suitable. cyrrhetinate 3 g
DE19702050072 1970-10-12 1970-10-12 Aluminum tri-3-acetyl-18 betaglycyrrthetinate, process for its preparation and pharmaceutical preparations containing it Expired DE2050072C3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19702050072 DE2050072C3 (en) 1970-10-12 1970-10-12 Aluminum tri-3-acetyl-18 betaglycyrrthetinate, process for its preparation and pharmaceutical preparations containing it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19702050072 DE2050072C3 (en) 1970-10-12 1970-10-12 Aluminum tri-3-acetyl-18 betaglycyrrthetinate, process for its preparation and pharmaceutical preparations containing it

Publications (3)

Publication Number Publication Date
DE2050072A1 DE2050072A1 (en) 1972-04-20
DE2050072B2 true DE2050072B2 (en) 1974-06-06
DE2050072C3 DE2050072C3 (en) 1975-01-30

Family

ID=5784887

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19702050072 Expired DE2050072C3 (en) 1970-10-12 1970-10-12 Aluminum tri-3-acetyl-18 betaglycyrrthetinate, process for its preparation and pharmaceutical preparations containing it

Country Status (1)

Country Link
DE (1) DE2050072C3 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU553789B2 (en) * 1982-06-30 1986-07-24 Biorex Laboratories Ltd. Glycyrrhetinic acid derivatives in cream compositions
SI1663185T1 (en) * 2003-09-22 2009-04-30 Onepharm Res & Dev Gmbh Prevention and treatment of inflammation-induced and/or immune-mediated bone loss

Also Published As

Publication number Publication date
DE2050072A1 (en) 1972-04-20
DE2050072C3 (en) 1975-01-30

Similar Documents

Publication Publication Date Title
AT389871B (en) METHOD FOR PRODUCING BETA, GAMMA -DIHYDROPOLYPRENYL ALCOHOL DERIVATIVES
DE2003430C3 (en) p-Benzoylphenoxyisobutyric acid esters, their preparation and pharmaceuticals containing them
DE2549783A1 (en) TRIGLYCERIDE WITH AN ANTI-INFLAMMATORY EFFECT
DE2947624A1 (en) BETA, GAMMA -DIHYDROPOLYPRENYL ALCOHOL AND HEM-PRESSURING MEDICINE CONTAINING THEM
EP0029247A1 (en) Alkenyl thienyl alkane carboxylic acids and their derivatives, process for their preparation and medicaments containing them
DE68915269T2 (en) POLYVALENT ANTI-FLAMMING AGENT.
EP0100516B1 (en) 3-beta-(3&#39;-(carboxypropionyloxy))-ursa-9(11),12-dience-28-carboxylic acid and its salts, process for its preparation and medicines containing these compounds
EP0043548B1 (en) Salt of furosemide or piretanide as acid component and penbutolol as base component and pharmaceutical composition containing both of the said components
DE2050072C3 (en) Aluminum tri-3-acetyl-18 betaglycyrrthetinate, process for its preparation and pharmaceutical preparations containing it
DE1192635B (en) Process for the production of bismuth pectinate
DE2748291B2 (en) Substituted 13-benzodioxan-4ones and processes for their preparation and the use of these compounds in combating inflammation
DE2434929A1 (en) ACETAMINOPHENESTERS OF ARYLSALICYL ACIDS
EP0308665B1 (en) 5-aminosalicylic acid salts and pharmaceutical preparations containing them
DE1543733C3 (en) Aluminum bis-alpha- (p-chlorophenoxy) isobutyrate and brightening agents containing this compound as an active ingredient
DE929665C (en) Process for the preparation of therapeutically active streptomycin and dihydrostreptomycin salts
EP0498011B1 (en) Salts of the 2-(2,6-dichloroanilino)-phenylacetic acid, process for their preparation and their application as pharmaceutical preparations for topical use
DE2538292A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ORGANOSILICIUM COMPOUNDS
DE2839311C2 (en) Anti-ulcer pharmaceutical preparation
DE2511852A1 (en) NEW WIDE-SPECTRUM ANTIBIOTICS
DE2436959C2 (en) ANTIBACTERIAL COMPOSITION CONTAINING A 3-FLUOR-D-ALANINE TYPE COMPOUND AND AN N-SUBSTITUTED CYCLOSERINE COMPOUND
DE2141357C3 (en) Bis (4-chlorophenoxy) acetic acid esters, process for their preparation, medicaments containing these compounds
DE1076684B (en) Process for the preparation of pharmacologically active compounds of glycyrrhetinic acid
DE2503135A1 (en) TERPENS, THE METHOD OF MANUFACTURING IT AND MEDICINAL PRODUCTS CONTAINING THESE PRODUCTS
DE1802569C3 (en) Baicalein esters and process for their preparation
DE3037598C2 (en) Lysine and arginine salts of 5- (2,4-difluorophenyl) -2-hydroxybenzoic acid, process for their preparation and medicaments containing them

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)
E77 Valid patent as to the heymanns-index 1977